drugset
drugset / Trial / NCT04524403

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

NCT04524403 ↗

Phase 2 Completed 150 enrolled Corcept Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic medications.

Timeline

Start
2020-09-09
Primary completion
2022-07-29
Completion
2022-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Miricorilant Small molecule 600 mg Oral
Subject Miricorilant Small molecule 900 mg Oral

Indications

No indication recorded.